Richard Wilson, Astellas SVP, primary focus lead – genetic regulation
Following clinical hold lift, Astellas posts early Pompe gene therapy data
Fresh out of a clinical hold, Astellas is spotlighting data on its gene therapy for Pompe disease.
In four patients who got an infusion of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
